000267914 001__ 267914
000267914 005__ 20240403131603.0
000267914 0247_ $$2doi$$a10.1002/acn3.51969
000267914 0247_ $$2pmid$$apmid:38111972
000267914 0247_ $$2pmc$$apmc:PMC10863922
000267914 0247_ $$2altmetric$$aaltmetric:158422082
000267914 037__ $$aDZNE-2024-00182
000267914 041__ $$aEnglish
000267914 082__ $$a610
000267914 1001_ $$00000-0001-9731-4169$$aAbdelhak, Ahmed$$b0
000267914 245__ $$aSerum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.
000267914 260__ $$aChichester [u.a.]$$bWiley$$c2024
000267914 3367_ $$2DRIVER$$aarticle
000267914 3367_ $$2DataCite$$aOutput Types/Journal article
000267914 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1708339208_1853
000267914 3367_ $$2BibTeX$$aARTICLE
000267914 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000267914 3367_ $$00$$2EndNote$$aJournal Article
000267914 520__ $$aProgression prediction is a significant unmet need in people with progressive multiple sclerosis (pwPMS). Studies on glial fibrillary acidic protein (GFAP) have either been limited to single center with relapsing MS or were based solely on Expanded Disability Status Scale (EDSS), which limits its generalizability to state-of-the-art clinical settings and trials applying combined outcome parameters.Serum GFAP and NfL (neurofilament light chain) were investigated in EmBioProMS participants with primary (PP) or secondary progressive MS. Six months confirmed disability progression (CDP) was defined using combined outcome parameters (EDSS, timed-25-foot walk test (T25FW), and nine-hole-peg-test (9HPT)).243 subjects (135 PPMS, 108 SPMS, age 55.5, IQR [49.7-61.2], 135 female, median follow-up: 29.3 months [17.9-40.9]) were included. NfL (age-) and GFAP (age- and sex-) adjusted Z scores were higher in pwPMS compared to HC (p < 0.001 for both). 111 (32.8%) CDP events were diagnosed in participants with ≥3 visits (n = 169). GFAP Z score >3 was associated with higher risk for CDP in participants with low NfL Z score (i.e., ≤1.0) (HR: 2.38 [1.12-5.08], p = 0.025). In PPMS, GFAP Z score >3 was associated with higher risk for CDP (HR: 2.88 [1.21-6.84], p = 0.016). Risk was further increased in PPMS subjects with high GFAP when NfL is low (HR: 4.31 [1.53-12.13], p = 0.006).Blood GFAP may help identify pwPPMS at risk of progression. Combination of high GFAP and low NfL levels could distinguish non-active pwPMS with particularly high progression risk.
000267914 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000267914 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000267914 650_2 $$2MeSH$$aMale
000267914 650_2 $$2MeSH$$aHumans
000267914 650_2 $$2MeSH$$aFemale
000267914 650_2 $$2MeSH$$aMiddle Aged
000267914 650_2 $$2MeSH$$aMultiple Sclerosis
000267914 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein
000267914 650_2 $$2MeSH$$aIntermediate Filaments
000267914 650_2 $$2MeSH$$aBiomarkers
000267914 650_2 $$2MeSH$$aNeoplasm Recurrence, Local
000267914 650_2 $$2MeSH$$aMultiple Sclerosis, Chronic Progressive: diagnosis
000267914 650_7 $$2NLM Chemicals$$aGFAP protein, human
000267914 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000267914 650_7 $$2NLM Chemicals$$aBiomarkers
000267914 7001_ $$aAntweiler, Kai$$b1
000267914 7001_ $$aKowarik, Markus C$$b2
000267914 7001_ $$00000-0002-2737-7495$$aSenel, Makbule$$b3
000267914 7001_ $$aHavla, Joachim$$b4
000267914 7001_ $$aZettl, Uwe K$$b5
000267914 7001_ $$aKleiter, Ingo$$b6
000267914 7001_ $$aSkripuletz, Thomas$$b7
000267914 7001_ $$aHaarmann, Axel$$b8
000267914 7001_ $$aStahmann, Alexander$$b9
000267914 7001_ $$aHuss, Andre$$b10
000267914 7001_ $$aGingele, Stefan$$b11
000267914 7001_ $$aKrumbholz, Markus$$b12
000267914 7001_ $$aBenkert, Pascal$$b13
000267914 7001_ $$00000-0002-6963-8892$$aKuhle, Jens$$b14
000267914 7001_ $$00000-0001-5347-7441$$aFriede, Tim$$b15
000267914 7001_ $$0P:(DE-2719)2812633$$aLudolph, Albert C$$b16$$udzne
000267914 7001_ $$00000-0001-8372-3615$$aZiemann, Ulf$$b17
000267914 7001_ $$00000-0001-7509-5268$$aKümpfel, Tania$$b18
000267914 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b19$$udzne
000267914 773__ $$0PERI:(DE-600)2740696-9$$a10.1002/acn3.51969$$gVol. 11, no. 2, p. 477 - 485$$n2$$p477 - 485$$tAnnals of Clinical and Translational Neurology$$v11$$x2328-9503$$y2024
000267914 8564_ $$uhttps://pub.dzne.de/record/267914/files/DZNE-2024-00182%20SUP.docx
000267914 8564_ $$uhttps://pub.dzne.de/record/267914/files/DZNE-2024-00182.pdf$$yOpenAccess
000267914 8564_ $$uhttps://pub.dzne.de/record/267914/files/DZNE-2024-00182.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000267914 8564_ $$uhttps://pub.dzne.de/record/267914/files/DZNE-2024-00182%20SUP.doc
000267914 8564_ $$uhttps://pub.dzne.de/record/267914/files/DZNE-2024-00182%20SUP.odt
000267914 8564_ $$uhttps://pub.dzne.de/record/267914/files/DZNE-2024-00182%20SUP.pdf
000267914 909CO $$ooai:pub.dzne.de:267914$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000267914 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812633$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000267914 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002007$$aExternal Institute$$b19$$kExtern
000267914 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000267914 9141_ $$y2024
000267914 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-22
000267914 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000267914 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN CLIN TRANSL NEUR : 2022$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:11Z
000267914 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:11Z
000267914 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000267914 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bANN CLIN TRANSL NEUR : 2022$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000267914 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-04-16T15:13:11Z
000267914 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center Ulm$$lClinical Study Center Ulm$$x0
000267914 980__ $$ajournal
000267914 980__ $$aVDB
000267914 980__ $$aUNRESTRICTED
000267914 980__ $$aI:(DE-2719)5000077
000267914 9801_ $$aFullTexts